Mechanistic Rationales for Novel and Emerging Treatments for Psoriatic Arthritis: Plugging the Data into the Equation


Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Weill Cornell Medicine
Attending Rheumatologist and Co-Director, Clinic for Inflammatory Arthritis, Hospital for Special Surgery, New York, NY
Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Allan Gibofsky, MD, JD, MACR, FACP, FCLM, serves as Professor of Medicine in the Department of Healthcare Policy and Research at Weill Cornell Medicine. Dr Gibofsky is an attending physician and rheumatologist at the Hospital for Special Surgery, where he is Co- Director of the Clinic for Inflammatory Arthritis. He received his undergraduate degree from Brooklyn College of the City University of New York, his medical degree from Weill Medical College of Cornell University, and his law degree from Fordham University School of Law. He did his internship in pathology, followed by a residency in medicine at New York Hospital. He completed a fellowship in rheumatology/immunology jointly at Hospital for Special Surgery and at The Rockefeller University. Dr Gibofsky has authored or co-authored numerous papers and textbook chapters, primarily on rheumatic diseases and legal aspects of medical practice. He is known for his work on mechanisms of host-microbe interactions in rheumatology, and, in particular, for his basic and clinical studies on rheumatic fever.

Currently Secretary-Treasurer of The New York Rheumatism Association, Dr Gibofsky is past Chair of the Medical & Scientific Committee of the New York Chapter of The Arthritis Foundation and is a recipient of its Physicians’ Leadership Award. He also served as a member of the local and national Arthritis Foundation Board of Trustees and was Chair for Professional Education. Dr Gibofsky has participated in numerous professional and public education programs, nationally and internationally. He served as President of The American College of Rheumatology and was recently named a Master. Dr Gibofsky is a Jonas Salk Scholar of the City University and an Alumnus of the Year of Brooklyn College. He is past President of the American College of Legal Medicine and is past Chair of the American Board of Legal Medicine. Dr Gibofsky is past Chair of the Arthritis Advisory Committee of the Food and Drug Administration and continues as a special consultant to that committee.

Anthony Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology Departments of Dermatology and Pathology
Dermatology and Plastic Surgery Institute Cleveland Clinic Cleveland, OH
Anthony Fernandez, MD, PhD

Anthony P. Fernandez, MD, PhD, completed his dermatology residency at the University of Miami, Florida and a dermatopathology fellowship at the Cleveland Clinic. He is currently a staff physician at the Cleveland Clinic in Cleveland, Ohio where he practices both medical dermatology and dermatopathology and serves as Director of medical dermatology and the W.D. Steck Chair of Clinical Dermatology. He is also Co-Medical Director of Continuing Medical Education at the Cleveland Clinic and Assistant Professor of Clinical Medicine at the Cleveland Clinic Lerner College of Medicine.

Clinically, Dr. Fernandez specializes in treatment of systemic autoimmune and inflammatory diseases with prominent cutaneous involvement. His research interests mirror his clinical interests, with ongoing projects involving psoriasis, dermatomyositis, lupus erythematosus, cutaneous vasculitis, and pemphigus vulgaris. He is also active in a variety of national professional organizations, such as the American Academy of Dermatology, the Americans Society of Dermatopathology, and the Rheumatologic Dermatology Society. Dr. Fernandez is currently an Associate Editor for the Journal of the American Academy of Dermatology and a member of Healio’s Dermatology and Psoriasis Peer Perspective Boards.

Statement of Need

Psoriatic arthritis (PsA) can have serious debilitating effects on peripheral joints, the spine, tendon insertions, and fingers. Management of PsA has improved with therapies such as nonpharmacologic and symptomatic treatments, oral small molecules, tumor necrosis factor inhibitors, interleukin (IL)-12/23 inhibitors, IL-17 inhibitors, CTLA4-lg, Janus kinase (JAK)/TyK2 inhibitors, and IL-23 inhibitors; however, complete disease control has not yet been achieved.

This CME Outfitters Snack focuses on evaluating the mechanistic rationale for novel and emerging treatments for PsA as well as assessing safety and efficacy data for current and emerging JAK inhibitors to determine their role in the management of PsA in order to help narrow the treatment gap.

Learning Objectives

At the end of this CME/CE activity, participants should be able to assess the mechanistic rationale for novel and emerging treatments for psoriatic arthritis, including key clinical efficacy and safety data for targeted treatments.

Financial Support

Supported by an educational grant from Bristol Myers Squibb Company.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.

Dr. Fernandez reports that he receives grants from Mallinckrodt and Novartis. He receives research support from AbbVie Inc.; Corbus Pharmaceuticals Holdings, Inc.; Mallinckrodt Pharmaceuticals; and Pfizer Inc. He is on the speakers bureau for AbbVie Inc.; Mallinckrodt Pharmaceuticals; and Novartis. He is a consultant for AbbVie Inc.; Alexion Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Mallinckrodt Pharmaceuticals; and Novartis.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Michael J. Franks, MSN, AGACNP-BC, FNP, BC (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-030-H01-P


Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.


Mechanistic Rationales for Novel and Emerging Treatments for Psoriatic Arthritis: Plugging the Data into the Equation
Event Date: 01/22/2021